AU2012376221A1 - Compound comprising a MAO targeting/ seeker moiety for treating human gliomas - Google Patents

Compound comprising a MAO targeting/ seeker moiety for treating human gliomas Download PDF

Info

Publication number
AU2012376221A1
AU2012376221A1 AU2012376221A AU2012376221A AU2012376221A1 AU 2012376221 A1 AU2012376221 A1 AU 2012376221A1 AU 2012376221 A AU2012376221 A AU 2012376221A AU 2012376221 A AU2012376221 A AU 2012376221A AU 2012376221 A1 AU2012376221 A1 AU 2012376221A1
Authority
AU
Australia
Prior art keywords
compound
mao
chemotherapeutic
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012376221A
Other languages
English (en)
Inventor
David S. Baskin
Martyn Alun Sharpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Methodist Hospital
Original Assignee
The Methodist Hospital
The Methodist Hospital Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Methodist Hospital, The Methodist Hospital Research Institute filed Critical The Methodist Hospital
Publication of AU2012376221A1 publication Critical patent/AU2012376221A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2012376221A 2011-10-31 2012-10-31 Compound comprising a MAO targeting/ seeker moiety for treating human gliomas Abandoned AU2012376221A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553854P 2011-10-31 2011-10-31
US61/553,854 2011-10-31
PCT/US2012/062850 WO2013151584A1 (en) 2011-10-31 2012-10-31 Compound comprising a mao targeting/ seeker moiety for treating human gliomas

Publications (1)

Publication Number Publication Date
AU2012376221A1 true AU2012376221A1 (en) 2014-06-19

Family

ID=47146760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012376221A Abandoned AU2012376221A1 (en) 2011-10-31 2012-10-31 Compound comprising a MAO targeting/ seeker moiety for treating human gliomas

Country Status (9)

Country Link
US (1) US10555936B2 (cg-RX-API-DMAC7.html)
EP (2) EP2804604A1 (cg-RX-API-DMAC7.html)
JP (1) JP6118808B2 (cg-RX-API-DMAC7.html)
KR (1) KR102110794B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136026B (cg-RX-API-DMAC7.html)
AU (1) AU2012376221A1 (cg-RX-API-DMAC7.html)
CA (1) CA2887928A1 (cg-RX-API-DMAC7.html)
HK (1) HK1204547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013151584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物
CN104710433B (zh) * 2014-01-23 2016-08-17 南京友怡医药科技有限公司 苯丁酸氮芥衍生物、制备方法及应用
US10807944B2 (en) * 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH09501147A (ja) * 1993-06-07 1997-02-04 ザ・ウエルカム・ファウンデーション・リミテッド モノアミンオキシダーゼを使用する免疫反応性試薬
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5612329A (en) 1995-06-05 1997-03-18 University Of Maryland At Baltimore Diaziridinylpolyamine anti-cancer agents
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
US6727361B2 (en) 2000-11-07 2004-04-27 Symyx Technologies, Inc. Phosphino substituted pyridine amine ligands
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US7943586B2 (en) 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
GB0513297D0 (en) 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
US20070275944A1 (en) 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物

Also Published As

Publication number Publication date
US10555936B2 (en) 2020-02-11
JP2014534227A (ja) 2014-12-18
KR102110794B1 (ko) 2020-05-15
US20140323513A1 (en) 2014-10-30
WO2013151584A1 (en) 2013-10-10
EP2804604A1 (en) 2014-11-26
CN104136026A (zh) 2014-11-05
EP3815685A2 (en) 2021-05-05
CN104136026B (zh) 2018-03-02
HK1204547A1 (en) 2015-11-27
JP6118808B2 (ja) 2017-04-19
KR20140128943A (ko) 2014-11-06
CA2887928A1 (en) 2013-10-10
EP3815685A3 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US8597949B2 (en) Methods and compositions for modulating RAD51 and homologous recombination
CN104788523B (zh) 用于核酸结合物的具有内涵体溶解剂的优化的体内递送系统
US20150292045A1 (en) Alternative uses for hbv assembly effectors
CN113166060A (zh) 用丙酮酸激酶激活化合物治疗镰状细胞病
US20120171227A1 (en) Pro-drug complexes and related methods of use
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
CN115433187B (zh) 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
MX2015000101A (es) Compuestos y usos terapéuticos de los mismos.
US12338244B2 (en) Temozolomide compounds, polymers prepared therefrom, and method of treating a disease
AU2022263701B2 (en) Use of medicament in treatment of tumor disease
US10555936B2 (en) Chemotherapeutic compositions and methods for treating human gliomas
EP4412720A1 (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
US20140364454A1 (en) Metal-chelating compounds having at least one polyamino chain
US9566351B2 (en) Molecular containers and methods of making and using same
US9206193B2 (en) Substituted norindenoisoquinolines, syntheses thereof, and methods of use
US20170029371A1 (en) Mao inhibitors and their conjugates as therapeutics for the treatment of brain cancer
WO2023131305A1 (zh) Prmt5抑制剂和抗癌治疗剂的组合
HK40041905A (en) Compound comprising a mao targeting/seeker moiety for treating human gliomas
US20130345231A1 (en) Anticancer therapeutic agents
JP2014534227A5 (cg-RX-API-DMAC7.html)
US11325905B2 (en) Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase
US20210212966A1 (en) Prodrug for therapeutic applications
AU2018367939B2 (en) Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
JP7724030B2 (ja) 腫瘍の治療における1,4-ジヒドロ-ナフチリジン系誘導体の使用
Zhou Dendrimer-Based Proteosomal Degradation of Indoleamine 2, 3-Dioxygenase 1 (IDO1)

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted